ARTICLE | Finance

Regulatory milestones

Highlights of weekly biotech stock moves

October 18, 2010 7:00 AM UTC

Alkermes Inc. (NASDAQ:ALKS) was off $1.12 to $14.80 last week after FDA approved an sNDA to extend the label of Vivitrol naltrexone to prevent relapse to opioid use in opioid-dependent patients following opioid detoxification. The injectable sustained-release formulation of naltrexone in polylactide co-glycolide polymer microspheres is marketed in the U.S. to treat alcohol dependence.

Allergan Inc. (NYSE:AGN) was up $1.54 to $68.86 last week after FDA approved an sBLA for Botox onabotulinumtoxin A to treat chronic migraine. Botox is already approved in the U.S. to treat severe primary axillary hyperhidrosis, cervical dystonia and strabismus, blepharospasm associated with dystonia and upper limb spasticity...